

# Muhammad Baluom

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2694064/publications.pdf>

Version: 2024-02-01

5  
papers

751  
citations

1684188  
5  
h-index

2053705  
5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

978  
citing authors

#	ARTICLE	IF	CITATIONS
1	R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 998-1008.	2.5	447
2	An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. <i>Arthritis and Rheumatism</i> , 2008, 58, 1433-1444.	6.7	160
3	Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1166-1176.	3.3	82
4	Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 78-88.	2.4	47
5	Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies. <i>Clinical Therapeutics</i> , 2015, 37, 2811-2822.	2.5	15